ARTICLE | Company News
CJ, Somaxon sales and marketing update
April 30, 2012 7:00 AM UTC
Somaxon granted CJ CheilJedang Corp. exclusive rights in South Korea to commercialize insomnia therapy Silenor doxepin. Somaxon will receive $600,000 up front and is eligible for sales milestones and...